Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedJan 06, 2026
DataAggregated Company Financials
Companies50
  • 7D-1.0%
  • 3M-1.7%
  • 1Y-7.6%
  • YTD0.4%

Over the last 7 days, the Biotech industry has dropped 1.0%, driven by a pullback from Vitrolife of 4.8%. Overall the industry is down 7.6% in 12 months. Earnings are forecast to grow by 30% annually.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 06 Jan 2026SEK 206.6bSEK 38.1b-SEK 556,373,959.9133.8x-371.4x5.4x
Thu, 04 Dec 2025SEK 204.2bSEK 38.1b-SEK 568,055,290.8231.8x-359.5x5.4x
Sat, 01 Nov 2025SEK 206.4bSEK 37.3b-SEK 1,198,953,801.4338.8x-172.2x5.5x
Mon, 29 Sep 2025SEK 192.5bSEK 36.4bSEK 3.0b31x63.6x5.3x
Wed, 27 Aug 2025SEK 198.2bSEK 36.1bSEK 2.8b30.7x70.3x5.5x
Fri, 25 Jul 2025SEK 193.2bSEK 35.9bSEK 2.8b28.8x69.2x5.4x
Sun, 22 Jun 2025SEK 179.0bSEK 35.2bSEK 2.2b28.1x80.3x5.1x
Tue, 20 May 2025SEK 193.8bSEK 33.9bSEK 1.2b34.8x161.3x5.7x
Thu, 17 Apr 2025SEK 175.2bSEK 33.7bSEK 756.5m29.4x231.6x5.2x
Sat, 15 Mar 2025SEK 196.7bSEK 33.7bSEK 579.2m33.2x339.6x5.8x
Mon, 10 Feb 2025SEK 220.8bSEK 33.7bSEK 271.3m56.5x814.1x6.6x
Wed, 08 Jan 2025SEK 222.5bSEK 33.0b-SEK 4,418,607,133.09161.4x-50.4x6.7x
Fri, 06 Dec 2024SEK 211.2bSEK 33.0b-SEK 4,445,339,784.56145x-47.5x6.4x
Sun, 03 Nov 2024SEK 215.9bSEK 33.2b-SEK 4,482,059,813.14138.3x-48.2x6.5x
Tue, 01 Oct 2024SEK 218.7bSEK 31.4b-SEK 5,543,334,290.8352.4x-39.5x7x
Thu, 29 Aug 2024SEK 210.8bSEK 31.4b-SEK 5,438,746,160.8950.7x-38.8x6.7x
Sat, 27 Jul 2024SEK 205.0bSEK 31.4b-SEK 5,423,607,425.0246.9x-37.8x6.5x
Mon, 24 Jun 2024SEK 193.1bSEK 30.6b-SEK 5,516,948,117.3039x-35x6.3x
Wed, 22 May 2024SEK 191.4bSEK 30.6b-SEK 5,500,926,223.4340.4x-34.8x6.3x
Fri, 19 Apr 2024SEK 177.7bSEK 29.8b-SEK 5,266,079,807.9163.7x-33.8x6x
Sun, 17 Mar 2024SEK 186.1bSEK 29.8b-SEK 5,636,600,511.9959.6x-33x6.2x
Tue, 13 Feb 2024SEK 174.2bSEK 29.6b-SEK 5,689,838,434.7960.8x-30.6x5.9x
Thu, 11 Jan 2024SEK 187.9bSEK 28.7b-SEK 1,198,150,867.0059.7x-156.8x6.5x
Sat, 09 Dec 2023SEK 169.9bSEK 28.7b-SEK 1,200,254,628.0058.4x-141.6x5.9x
Mon, 06 Nov 2023SEK 159.4bSEK 28.6b-SEK 1,294,362,402.0049x-123.1x5.6x
Wed, 04 Oct 2023SEK 161.2bSEK 27.4b-SEK 2,016,819,081.0047.9x-80x5.9x
Fri, 01 Sep 2023SEK 154.7bSEK 27.4b-SEK 2,041,245,894.0052.2x-75.8x5.7x
Sun, 30 Jul 2023SEK 156.0bSEK 27.5b-SEK 1,534,283,427.0055.8x-101.7x5.7x
Tue, 27 Jun 2023SEK 160.4bSEK 26.4b-SEK 1,312,502,366.0045.9x-122.2x6.1x
Thu, 25 May 2023SEK 171.9bSEK 26.3b-SEK 1,366,671,495.0045.3x-125.8x6.5x
Sat, 22 Apr 2023SEK 173.8bSEK 25.5b-SEK 2,076,006,783.0039.7x-83.7x6.8x
Mon, 20 Mar 2023SEK 166.1bSEK 25.4b-SEK 2,031,630,100.0038.8x-81.7x6.5x
Wed, 15 Feb 2023SEK 176.3bSEK 25.3b-SEK 1,663,705,349.0028.2x-106x7x
Fri, 13 Jan 2023SEK 170.4bSEK 23.8b-SEK 1,845,390,458.0031.6x-92.4x7.2x
Price to Earnings Ratio

-92.4x


Total Market Cap: SEK 170.4bTotal Earnings: -SEK 1,845,390,458.00Total Revenue: SEK 23.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -45.1x202420252026
Current Industry PE
  • Investors are pessimistic on the Swedish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 6.1x is higher than the industry's current PS ratio of 5.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Revenues for these companies have grown 17% per year.
  • This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market0.56%
Healthcare-1.80%
Biotech-1.02%
Biotech-1.02%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 333.800.1%
+SEK 137.9m		4.7%PE8849.7x
HAMLET B Hamlet BioPharmaSEK 4.2014.3%
+SEK 93.3m		1.4%PS4191x
SUBGEN Subgen AISEK 1.028.0%
+SEK 39.0m		n/an/a
MVIR MedivirSEK 0.4618.9%
+SEK 32.8m		-85.5%PS51.8x
BIOVIC B Biovica InternationalSEK 0.4431.0%
+SEK 30.7m		-77.1%PS13.1x

Latest News

SOBI
SEK 333.80
Swedish Orphan Biovitrum
7D
0.1%
1Y
4.7%

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Jan 05
Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly
VICO
SEK 10.54
Vicore Pharma Holding
7D
-8.5%
1Y
12.1%
EGTX
SEK 5.03
Egetis Therapeutics
7D
-4.7%
1Y
-26.7%
CRNO B
SEK 6.69
Cereno Scientific
7D
-4.8%
1Y
19.6%
BIOG B
SEK 105.60
BioGaia
7D
0.3%
1Y
-4.5%
MVIR
SEK 0.46
Medivir
7D
18.9%
1Y
-85.5%
BIOA B
SEK 309.60
BioArctic
7D
-1.2%
1Y
46.0%

BIOA B Future Long Term Margin Upside Will Not Offset Demand Risks

Analysts have modestly raised their price target on BioArctic to SEK 230 (from SEK 230 previously), reflecting slightly lower perceived risk and a substantially improved long term profit margin outlook, despite marginally weaker revenue growth assumptions and a lower projected future P/E multiple. What's in the News Leqembi, developed by BioArctic and Eisai, has been included in China’s new Commercial Insurance Innovative Drug List.
VITR
SEK 131.30
Vitrolife
7D
-4.8%
1Y
-39.6%

VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential

Analysts have slightly reduced their price target on Vitrolife, trimming fair value by SEK 4.75 to SEK 188.75, as modestly higher long term growth assumptions are offset by a small downgrade to profitability and a lower expected valuation multiple. What's in the News Vitrolife plans to record a SEK 5.4 billion goodwill impairment in the fourth quarter of 2025 related to the Igenomix acquisition (company announcement).
SYNACT
SEK 21.40
SynAct Pharma
7D
-7.2%
1Y
132.6%
BIOVIC B
SEK 0.44
Biovica International
7D
31.0%
1Y
-77.1%

BIOVIC B: U.S. Cancer Center Adoption Will Drive Future Biomarker Demand

Analysts have trimmed their price target for Biovica International from SEK 3.00 to SEK 1.80, citing slightly slower projected revenue growth, lower expected profit margins, and a more conservative valuation multiple as the key drivers of the downward revision. What's in the News Signed a commercial agreement with a leading U.S. NCI-designated Comprehensive Cancer Center, enabling clinicians to order DiviTum TKa for routine clinical use in breast cancer and simplifying ordering and billing workflows (company announcement).
BONEX
SEK 182.70
Bonesupport Holding
7D
-3.5%
1Y
-54.3%

BONEX: De Novo Pathway Shift Will Support Strong Future Market Position

Analysts have modestly raised their price target on Bonesupport Holding, citing a slightly lower discount rate and improved visibility into sustaining approximately 38 percent revenue growth and robust 31 percent profit margins. Together, these factors support a fair value of SEK 391.20 per share.
IMMU
SEK 6.00
Mendus
7D
9.1%
1Y
-29.0%
HNSA
SEK 31.68
Hansa Biopharma
7D
-3.7%
1Y
-20.4%
SUBGEN
SEK 1.02
Subgen AI
7D
8.0%
1Y
n/a
INIT
SEK 3.01
Initiator Pharma
7D
8.3%
1Y
-59.3%
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%